...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and applied thrombosis/hemostasis : >Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease
【24h】

Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease

机译：冠状动脉疾病稳定的糖尿病患者药物洗脱支架植入后冠状动脉再狭窄的新型生物标志物

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The purpose of the study was to assess whether the occurrence of restenosis is associated with CD45+ platelet count and neutrophil to lymphocyte ratio in patients with type 2 diabetes mellitus (DM) after drug-eluting stent (DES) implantation for stable coronary artery disease (CAD). The study comprised 126 patients, including 55 patients with type 2 DM and stable CAD who underwent elective coronary artery stenting with DES and follow-up angiography within 6 to 12 months. Blood samples were collected from each patient on the morning of the coronary angiography procedure. The variables related to in-stent restenosis were selected by logistic regression analysis. The logistic regression analysis showed that 2 inflammatory factors, CD45+ platelet count (odds ratio [OR] = 4.51, 95% confidence interval [CI]: 1.50-13.50, P = .007) and neutrophil to lymphocyte ratio (OR = 3.09, 95% CI: 1.05-9.10, P = .04), were significantly associated with the risk of in-stent restenosis after stenting with DES in patients with stable CAD and type 2 DM. A receiver operator characteristic curve analysis indicated that the area under the curve was 0.83% (0.05%; P .001), which showed that the logistic model had good predictive accuracy (based on CD45+ platelet count and neutrophil to lymphocyte ratio) for the risk of in-stent restenosis development in DES in patients with CAD and type 2 DM. Two novel biomarkers of restenosis, CD45+ platelet count and neutrophil to lymphocyte ratio, may be effectively used to predict in-stent restenosis after DES implantation in patients with CAD and type 2 DM.
机译：该研究的目的是评估在为稳定的冠状动脉疾病（CAD）植入药物洗脱支架（DES）后2型糖尿病（DM）患者中再狭窄的发生是否与CD45 +血小板计数和嗜中性白细胞与淋巴细胞比率有关）。该研究包括126例患者，包括55例2型DM和稳定CAD的患者，他们在6至12个月内接受了DES选择性冠状动脉支架置入术并进行了后续血管造影。在冠状动脉造影步骤的早晨从每位患者收集血样。通过logistic回归分析选择与支架内再狭窄相关的变量。 Logistic回归分析显示有2种炎症因子，CD45 +血小板计数（几率[OR] = 4.51，95％置信区间[CI]：1.50-13.50，P = .007）和中性白细胞与淋巴细胞的比率（OR = 3.09，95） ％CI：1.05-9.10，P = .04）与稳定CAD和2型DM患者经DES支架置入后支架内再狭窄的风险显着相关。接收者操作者特征曲线分析表明，曲线下面积为0.83％（0.05％; P <.001），这表明该逻辑模型具有良好的预测准确性（基于CD45 +血小板计数和嗜中性白细胞与淋巴细胞的比率）。 CAD和2型DM患者的DES发生支架内再狭窄的风险。两种新的再狭窄生物标志物CD45 +血小板计数和嗜中性白细胞与淋巴细胞比率可有效地用于预测DES植入后CAD和2型DM患者的支架内再狭窄。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号